Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with kidney disease. Founded in 2007, Akebia has made significant strides in the industry, particularly in the area of hypoxia-inducible factor (HIF) stabilisation, which plays a crucial role in managing anaemia associated with chronic kidney disease. The company’s flagship product, vadadustat, is designed to treat anaemia by stimulating erythropoiesis, offering a unique oral alternative to traditional injectable therapies. Akebia's commitment to advancing renal care has positioned it as a notable player in the biopharmaceutical landscape, with a strong emphasis on research and development. With a focus on improving patient outcomes, Akebia continues to explore new avenues in the treatment of kidney-related conditions, solidifying its reputation as an innovator in the field.
DitchCarbon Score
How does Akebia Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akebia Therapeutics, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akebia Therapeutics, Inc.'s reported carbon emissions
Akebia Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). Additionally, there are no documented climate commitments or initiatives aimed at reducing greenhouse gas emissions. As the biopharmaceutical industry increasingly focuses on sustainability, Akebia's lack of disclosed climate strategies may reflect a broader trend within the sector, where many companies are still developing their environmental policies.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akebia Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
